Navigation Links
Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
Date:11/15/2013

ATLANTA, Nov. 15, 2013 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2). These findings, presented for the first time at Obesity Week 2013 on November 15, 2013, demonstrated significant weight loss and improvements in cardiometabolic risk markers in 147 obese individuals over 12 weeks of treatment, the largest and longest trial to date for the beloranib program.

"The latest results from this robust, larger scale trial represent the first full set of Phase 2 data for beloranib in severely obese patients," said Thomas Hughes, Ph.D., President and CEO of Zafgen.  "This patient population often remains beyond the reach of existing pharmacotherapy and there is a major unmet medical need for treatment of this serious disease.  We are very encouraged by the extent of weight loss observed in this trial and will continue to pursue beloranib as a pharmacological alternative to bariatric surgery."

Beloranib, a novel obesity therapy that utilizes a unique mechanism of action, is being studied for its ability to reduce body weight and improve cardiometabolic risk factors in obese patients.  The study presented was a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a dose range of beloranib administered as twice-weekly subcutaneous injections for 12 weeks.  The trial enrolled 147 patients, of which 122 completed the study.  Subjects were mostly obese women with mean age 48.4 years, body weight (BW) 100.9  kg, and body mass index (BMI) 37.6 kg/m2, who were enrolled into one of the four arms of the trial (N=37 in 0.6 mg, 37 in 1.2 mg, 35 in 2.4 mg and 38 in placebo arm). Patients
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... and BOSTON , September 16, 2014 ... Scientific Officer, Fiona Marshall , will give a presentation ... protein-coupled receptors using StaR ®   technology ... in Drug Discovery and Development " virtual symposium run by ... Society. The virtual symposium is on Wednesday, 24 September 2014; ...
(Date:9/15/2014)... , Sept. 16, 2014 The French ... (HNF) announced today an agreement to collaborate on programs ... support the development of a stronger CMT patient and ... support to several HNF,s initiatives including: , ... the HNF website featuring  HNF newsletters, materials and latest ...
(Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... Nov. 5, 2010 EnVivo Pharmaceuticals today announced it ... agonist, possesses a novel mechanism not previously seen in ... Acetylcholine (ACh) to enhance cognition. By acting ... makes it possible for smaller amounts of naturally occurring ...
... Nov. 5, 2010 Cadence Pharmaceuticals, Inc. (Nasdaq: ... developing and commercializing proprietary product candidates principally for use ... the three and nine months ended September 30, 2010. ... U.S. Food and Drug Administration (FDA) approved OFIRMEV™ (acetaminophen) ...
Cached Medicine Technology:EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 2Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 3Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 4Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 5Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 6
(Date:9/16/2014)... QuickMedical, a national leader in the ... veteran-owned small business has officially launched three new ... Nipro Medical, and CP Medical Sutures. , ... best, most affordable medical equipment and supplies. To ... effort to reach new medical facilities, QuickMedical has ...
(Date:9/16/2014)... Richmond, VA (PRWEB) September 16, 2014 ... Museum of Virginia this fall. Reflecting on what it ... Ethics: Expanding Community Vision investigates unique and thought-provoking topics. ... people to be inspired to look at their world ... provoking and set the stage for truly enlightening dialogue,” ...
(Date:9/16/2014)... Today, the Diamond in the Raw Foundation ... held, Sunday, October 19, 2014 at the Skirball Cultural ... show honors the dare-devil stuntwomen of film and television ... Over 12 categories will be recognized in the two-hour ... , Special honors will be given to legendary stuntwomen ...
(Date:9/16/2014)... N.C. (PRWEB) September 16, 2014 Triad ... President & CEO of Intersil and former President of ... of directors. , “David has extraordinary technology and business ... Triad’s board of directors,” said Lynn Hayden, Triad CEO ... years of analog and mixed signal semiconductor experience to ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 A peep-toe ... back, bootie, or any other dress shoe) in which ... the toes to show. Peep-toe shoes were popular beginning ... shoes had a brief resurgence in the 1970s/80s, before ... they have enjoyed some popularity again, with variations such ...
Breaking Medicine News(10 mins):Health News:Expanding Community Vision at the Science Museum of Virginia 2Health News:Hollywood's Action Icon Awards to Honor Legendary Stuntwomen In A Star-Studded Gala and Awards Ceremony 2Health News:David Bell Joins Triad Semiconductor's Board of Directors 2Health News:Nice Peep Toes Are For Sale At Fecbek.com 2
... THURSDAY, Dec. 15 (HealthDay News) -- Lack of time is ... suggests that several short intensive workouts a week may help ... regimens. The small, new study found that 30 ... time of 75 minutes a week with warm-up and cool-down ...
... -- Nearly 20 million Americans who see a dentist at ... general health care provider, which suggests that dentists could screen ... pressure, diabetes and heart disease, a new study says. ... adults who took part in the 2008 U.S. National Health ...
... , THURSDAY, Dec. 15 (HealthDay News) - To catch cervical ... human papillomavirus (HPV) test is the best option for women ... with the more traditional Pap smear resulted in earlier detection ... developing, said study author Dr. Chris Meijer, a professor of ...
... researchers at the University of Alberta have discovered a new ... those living with the disease, by using a powerful, triple ... brain tissue. The researchers discovered that iron levels in ... brain that are responsible for relaying messages. High iron levels ...
... coffee maker, and the simple quest becomes, well, an ordeal. After ... you finally make a purchase, only to wonder: "Was this the ... Reality check: Is this you? If so, new research ... to make a decision that you,ll be happy with. Joyce ...
... (HealthDay News) -- Low levels of iron in the blood ... that form in a vein, according to the results of ... vessel disease. The findings suggest that treating iron deficiency ... (DVT), according to the researchers at Imperial College London in ...
Cached Medicine News:Health News:Brief, Intense Exercise Lowers Blood Sugar, Small Study Finds 2Health News:Brief, Intense Exercise Lowers Blood Sugar, Small Study Finds 3Health News:Dentists Could Fill Gap in Health Care, Study Says 2Health News:HPV Test Spots Cervical Cancer Earlier Than Pap Smear: Study 2Health News:HPV Test Spots Cervical Cancer Earlier Than Pap Smear: Study 3Health News:Using powerful MRI to track iron levels in brain could be new way to monitor progression of MS 2Health News:Psychology researcher finds that second-guessing one's decisions leads to unhappiness 2Health News:Psychology researcher finds that second-guessing one's decisions leads to unhappiness 3Health News:Low Iron Levels May Increase Blood Clot Risk 2
... the corrosion resistance of stainless steel ... copper, SANYO offers an electro-polished copper-alloy-stainless ... maintenance-free. The sterile environment promotes the ... and the safety of laboratory staff. ...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
Undercounter Freezer -25C. White. Front opening freezer. 4 cubic ft capacity. Reversible door. Three slide-out drawers. Extra thick CFC insulation. Front lock. Front indicator lights. Attractive tabl...
... F 265 is a highly accurate portable, waterproof ... temperature measurements. Temperature compensated pH results can be ... or a 3-in-1 electrode. • This GLP/GMP compliant ... a printer or a computer. Up to 100 ...
Medicine Products: